Φορτώνει......
Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
OBJECTIVE: Acquired T790M mutations account for 50%–60% of tyrosine kinase inhibitor (TKI)-resistant mechanisms in EGFR mutation-positive (m+) non-small-cell lung cancer (NSCLC) patients, and re-biopsy is recommended to detect these mutations. We investigated the re-biopsy status and the T790M incid...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Onco Targets Ther |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6208793/ https://ncbi.nlm.nih.gov/pubmed/30464499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S174075 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|